falconer66a Tuesday, 06/04/19 03:21:49 PM
Re: FitzyP33 post# 195401 0
Post # of 195419
I’m Not Seeing the Paper As Really Important
Quote:
...the promise of a scientific publication laying out long term findings. I'm sure I'm being impatient, but where is it?
What this paper is supposed to reveal; even who’s to write it, are mysteries to me.

But after all the many years I’ve been invested in Anavex Life Sciences Corp and scrutinized (and understood) the profound science that undergirds the company’s future, I’ve come to realize that just a few things will bring that on (at markedly elevated share prices).

One of those things WILL NOT be any sort of scientific publication. The stark realization is this. Share prices of pharmaceuticals placing their futures on treatments for central nervous system diseases can no longer be controlled or influenced by positive academic papers or reports. They simply have no influence, now, on companies such as Anavex. Would be glad to be wrong; to find that the AVXL share price steeply ascends when some new scientific report appears.

But I think the chances of that are meager. I’m not much reading the posts now on AVXL. Nothing substantial is going to change until externally-reported news on Anavex 2-73 appears in popular media; the New York Times, or major network evening news. And that will have to be news of clinical success in one of the three trials now underway. When the non-business, non-investment news media tell that patients taking Anavex 2-73 have been measured to be better, that will be listened to.

“Wait! Did you hear that? Some company down in Australia is fixing the Alzheimer’s problem. And the same drug is fixing Spaniards with Parkinson’s. I gotta check this out.”

The people “checking things out,” retail investors, don’t read, understand, or care about academic science reports. They have no idea about statistical significance, n numbers, double blindedness, endoplasmic reticula, or anything of the kind. As the present situation affirms, all of that is confusing (there are already good papers on Anavex science; of no market consequence).

The only thing that will count will be news media (not business news) reports of clinical successes in Spain and Australia. Those, most likely, will be late this year or early next. Then, the Anavex future will be golden. Until then, just more of all we’ve labored with here. From time to time, I’ll continue to check what’s being posted. But I’ve exhausted my ability to more clearly explain the science beneath the Anavex molecules. “Science” doesn’t, won’t count. Only people whose health have been reported to have improved will elevate the AVXL share price. Waiting....

https://investorshub.advfn.com/boards/read_ms...=149201468